A complete response to MEK inhibition was reported [66], and within the context of MPNST, clinical trials of Ras/Raf/MEK/ERK pathway inhibition are ongoing [67]. This evidence concerns the gene MAP2K7 and malignant peripheral nerve sheath tumor.